Overview

A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction

Status:
Active, not recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of a fixed dose of human corneal endothelial cells when administered with varying concentrations of Rho kinase inhibitor (Y-27632) in patients with corneal edema secondary to endothelial dysfunction.
Phase:
Phase 1
Details
Lead Sponsor:
Aurion Biotech